Of the 1680 NSCLC patients, 28 had tumors bearing BARF mutation (1.7%), 799 had tumors bearing EGFR mutation (47.6%), and 149 had tumors bearing KRAS mutation (8.9%). This evidence concerns the gene KRAS and non-small cell lung carcinoma.